Compare Amphastar Pharmaceuticals Inc (AMPH) vs 3M Company (MMM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs 3M Company — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while 3M Company trades at $157.3 (market cap $82.16B). The key difference: 3M Company is far larger — about 99.5× Amphastar Pharmaceuticals Inc's market cap, and 3M Company pays a 1.98% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MMM | |
|---|---|---|
Market Cap | $826.08M | $82.16B |
Sector | Health | Industrials |
52-Week High | $30.81 | $174.61 |
52-Week Low | $16.87 | $141.10 |
Enterprise Value | $1.22B | $90.56B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
3M (MMM) trades at $157.52, up 1.4% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with a 72.14% ROE and 13.03% net margin, though revenue has declined from 2022 peaks. Recent news highlights segment weakness in Consumer but strength in Safety & Industrial, alongside strategic partnerships like the Airbus A220 supply agreement.
Outlook is mixed: analyst consensus is cautious with a $148.75 price target below current levels, citing persistent consumer segment challenges. Investment appeal lies in dividend yield and cost optimization efforts, but risks include revenue stagnation and high debt levels. The stock faces headwinds from technical bearishness and modest growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
